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Abstract: PURPOSE Clinical positron emission tomography (PET) imaging of the presynaptic nore-
pinephrine transporter (NET) function provides valuable diagnostic information on sympathetic out-
flow and neuronal status. As data on the NET-targeting PET tracers [11C]meta-hydroxyephedrine
([11C]mHED) and [18F]LMI1195 ([18F]flubrobenguane) in murine experimental models are scarce or
lacking, we performed a detailed characterization of their myocardial uptake pattern and investigated
[11C]mHED uptake by kinetic modelling. METHODS [11C]mHED and [18F]LMI1195 accumulation in the
heart was studied by PET/CT in FVB/N mice. To test for specific uptake by NET, desipramine, a se-
lective NET inhibitor, was administered by intraperitoneal injection. [11C]mHED kinetic modelling with
input function from an arteriovenous shunt was performed in three mice. RESULTS Both tracers accu-
mulated in the mouse myocardium; however, only [11C]mHED uptake was significantly reduced by excess
amount of desipramine. Myocardial [11C]mHED uptake was half-saturated at 88.3 nmol/kg of combined
mHED and metaraminol residual. After [11C]mHED injection, a radiometabolite was detected in plasma
and urine, but not in the myocardium. [11C]mHED kinetics followed serial two-tissue compartment mod-
els with desipramine-sensitive K1. CONCLUSION PET with [11C]mHED but not [18F]LMI1195 provides
information on NET function in the mouse heart. [11C]mHED PET is dose-independent in the mouse
myocardium at < 10 nmol/kg of combined mHED and metaraminol. [11C]mHED kinetics followed serial
two-tissue compartment models with K1 representing NET transport. Myocardial [11C]mHED uptake
obtained from PET images may be used to assess cardiac sympathetic integrity in mouse models of
cardiovascular disease.
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ORIGINAL RESEARCH
[11C]mHED PET follows a two-tissue 
compartment model in mouse myocardium 
with norepinephrine transporter 
(NET)-dependent uptake, while  [18F]LMI1195 
uptake is NET-independent
Linjing Mu1,2† , Stefanie D. Krämer2† , Geoffrey I. Warnock1,3, Ahmed Haider1,3 , Susan Bengs1,3 ,  
Giovanni Cartolano2, Dominic S. Bräm2, Claudia Keller2, Roger Schibli2 , Simon M. Ametamey2 , 
Philipp A. Kaufmann1 and Catherine Gebhard1,3* 
Abstract 
Purpose: Clinical positron emission tomography (PET) imaging of the presynaptic norepinephrine transporter (NET) 
function provides valuable diagnostic information on sympathetic outflow and neuronal status. As data on the NET-
targeting PET tracers  [11C]meta-hydroxyephedrine  ([11C]mHED) and  [18F]LMI1195  ([18F]flubrobenguane) in murine 
experimental models are scarce or lacking, we performed a detailed characterization of their myocardial uptake pat-
tern and investigated  [11C]mHED uptake by kinetic modelling.
Methods: [11C]mHED and  [18F]LMI1195 accumulation in the heart was studied by PET/CT in FVB/N mice. To test for 
specific uptake by NET, desipramine, a selective NET inhibitor, was administered by intraperitoneal injection.  [11C]
mHED kinetic modelling with input function from an arteriovenous shunt was performed in three mice.
Results: Both tracers accumulated in the mouse myocardium; however, only  [11C]mHED uptake was significantly 
reduced by excess amount of desipramine. Myocardial  [11C]mHED uptake was half-saturated at 88.3 nmol/kg of 
combined mHED and metaraminol residual. After  [11C]mHED injection, a radiometabolite was detected in plasma and 
urine, but not in the myocardium.  [11C]mHED kinetics followed serial two-tissue compartment models with desipra-
mine-sensitive K1.
Conclusion: PET with  [11C]mHED but not  [18F]LMI1195 provides information on NET function in the mouse heart. 
 [11C]mHED PET is dose-independent in the mouse myocardium at < 10 nmol/kg of combined mHED and metarami-
nol.  [11C]mHED kinetics followed serial two-tissue compartment models with K1 representing NET transport. Myo-
cardial  [11C]mHED uptake obtained from PET images may be used to assess cardiac sympathetic integrity in mouse 
models of cardiovascular disease.
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Introduction
Cardiac sympathetic activation is an essential physi-
ological stress response adapting cardiac performance 
to increased workload [1]. However, persistent sympa-
thetic firing is also a key neurohormonal abnormality 
with major prognostic implications in many cardiovas-
cular conditions [2, 3]. Indeed, the contribution of sym-
pathetic hyperactivity to disease progression and adverse 
outcomes in heart failure patients is well established [2]. 
Moreover, patients with acute coronary syndrome show 
an elevated sympathetic activity, potentially owing to 
the interaction of the sympathetic nervous system with 
inflammatory processes [4]. Nevertheless, despite an 
improved understanding of autonomous dysbalance in 
ischemic heart disease and congestive heart failure, sig-
nificant knowledge gaps remain with respect to the detri-
mental effects of cardiac innervation and denervation on 
cardiovascular endpoints [5, 6].
The development of radioligands targeting the pre-
synaptic norepinephrine transporter (NET, "uptake-1", 
SLC6A2), such as the benzylguanidine analogue 
 [123I]meta-iodobenzylguanidine  ([123I]mIBG) for single-
photon emission computed tomography (SPECT) and 
the norfenefrine analogue  [11C]meta-hydroxyephedrine 
 ([11C]mHED,  [11C]HED) for positron emission tomog-
raphy (PET) has enabled the non-invasive assessment 
of the neurohumoral axis [7]. However, in clinical imag-
ing,  [123I]mIBG is limited by the moderate resolution of 
SPECT. The use of  [11C]mHED is challenged by the short 
half-life of 11C (20 min), spill-over from the liver in pre-
clinical imaging, and the fact that  [11C]mHED uptake in 
the mouse heart depends on the co-injected dose of its 
precursor metaraminol [8]. Thus, the PET tracer  [18F]
LMI1195  ([18F]flubrobenguane) has recently been intro-
duced [9]. This F-18 offers a longer physical half-life 
(110 min) than C-11 as well as improved spatial resolu-
tion in tissue due to lower energy of the β+ decay [10]. 
Despite the successful clinical validation of both  [11C]
mHED and  [18F]LMI1195, detailed studies of these trac-
ers in mice are scarce. This represents a major knowledge 
gap given that mouse models of cardiac disease provide 
a unique opportunity to identify molecular mechanisms 
accounting for the adverse effects of sympathetic dysreg-
ulation in cardiovascular risk and disease conditions.
We aimed to portray the uptake mechanisms of 
 [11C]mHED and  [18F]LMI1195 in the mouse myocar-
dium. Myocardial uptake of  [11C]mHED was analysed 
in detail, by taking into account tracer molar activity, 
biotransformation, and uptake kinetics. Finally, the utility 
of standardized uptake value (SUV) as a measure of NET 
function in the mouse myocardium was addressed.
Materials and methods
All chemicals, unless otherwise stated, were purchased 
from Sigma-Aldrich (Buchs, Switzerland), Acros Organ-
ics (Reinach, Switzerland), or Merck (Darmstadt, 
Germany) and used without further purification. Meta-
raminol bitartrate, the precursor for C-11 radiolabel-
ling, was obtained from ABX advanced biochemical 
compounds GmbH  (Radeberg, Germany). For NET 
inhibition,desipramine HCl (Sigma-Aldrich, Buchs, Swit-
zerland) was dissolved in water for injection at 10 mg/ml 
(corresponding to 9 mg/ml as base). The reference com-
pound 9 (LMI1195, Additional file  1) and the tosylate 
activated precursor 7 (Additional file  1) used for F-18 
radiolabelling were synthesized following the modified 
approach described by Purohit et al. [11]. The radiosyn-
theses of  [11C]mHED and  [18F]LMI1195 are described in 
Additional file 1.
Animals
Ten-week-old female FVB/N mice were obtained from 
Janvier Labs (Le Genest-Saint-Isle, France). The animals 
had free access to food and water. The mice were scanned 
at 12–14 weeks of age (20–24 g body weight).
Ex vivo radiometabolite studies
Mice were injected awake with formulated  [11C]mHED 
(26–173 MBq) via the tail vein. Animals were anaesthe-
tized with 5% isoflurane in oxygen/air (1:1) and eutha-
nized by decapitation at the indicated time points to 
collect blood, urine, and heart tissue. Plasma was sepa-
rated from blood by centrifugation (5000×g for 5 min at 
4 °C). Plasma and urine were each mixed with equal vol-
umes of ice-cold acetonitrile (MeCN) for protein precipi-
tation. The dissected heart was homogenized in 2 ml PBS, 
and proteins were precipitated with 2 ml ice-cold MeCN. 
The samples were centrifuged (5000×g, 4  °C), and the 
supernatants were filtered and analysed by radio-UPLC 
(Waters Acquity UPLC HSS T3 1.8 µm) with the follow-
ing separation conditions: 10 mM  NH4HCO3 (solvent A), 
MeCN (solvent B); 0.0–1.0  min, 5–30% B; 1.0–1.7  min, 
30% B; 1.7–1.8 min, 30–5% B and 1.8–3.0 min, 5% B at 
a flow rate of 0.5 ml/min (retention time: 1.75 min). The 
fraction of parent tracer radioactivity to total radioac-
tivity in plasma (fparent) was calculated as the ratio of 
Keywords: [11C]meta-hydroxyephedrine  ([11C]mHED), [18F]LMI1195  ([18F]flubrobenguane), Norepinephrine 
transporter (NET, SLC6A2), Cardiac sympathetic innervation imaging, Small animal PET, Kinetic modelling
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radioactivity in the  [11C]mHED peak and total detected 
radioactivity in the chromatogram. Equation 1 was fit to 
the data, using the nls function of R (R-project, version 
3.6.1).
In Eq.  1, q1 to q4 are the fit parameters (q3 was esti-
mated and fixed) and t is the time. Equation  1 was 
empirically defined, taking into account the exponential 
functions of time under linear kinetics and a lag phase for 
metabolite formation.
Ratio of plasma to whole blood radioactivity
For determining activity concentration ratios of plasma 
to whole blood in mice, 11–90  MBq  [11C]mHED were 
injected intravenously (i.v.) via the tail vein in awake 
mice. After anaesthesia, animals were euthanized at the 
indicated time points and blood was collected. An aliquot 
was centrifuged as described above to separate plasma 
from blood cells. Plasma and whole blood activity con-
centrations (Bq/ml) were determined by a gamma coun-
ter (Wizard 1480; Perkin Elmer) to calculate the plasma/
whole blood activity concentration ratio (ρplasma/blood). 
Bi-exponential function (Eq. 2) was fit to ρplasma/blood over 
time using the nls function of R.
In Eq. 2, r1 to r4 are the fit parameters and t is the time.
PET/CT acquisition
PET/computed tomography (CT) scans were per-
formed with a calibrated SuperArgus PET/CT scan-
ner (Sedecal, Madrid, Spain) with an axial field of view 
of 4.8  cm and a spatial resolution of 1.6–1.7  mm (full 
width at half maximum) [12]. Animals were under 
(1)







+ (1 − q1) × exp(− q4 × t)
(2)
ρplasma/blood = r1 × exp(− r3 × t) − r2 × exp(− r4 × t) + r2
anaesthesia with ~ 2.5% isoflurane in oxygen/air (1:1) 
for tracer injection into the tail vein and during the 
scan. For scans with NET inhibition, 20  mg desipra-
mine HCl was injected intraperitoneally (i.p.) 10  min 
before tracer i.v. injection when the animal was already 
under anaesthesia. For scans without kinetic model-
ling, tracer was injected into mouse tail vein on scan-
ner bed and the scan was started 1 min p.i. For kinetic 
modelling,  [11C]mHED was injected using the shunt 
system (see “Input function” section) on the scanner 
bed. Depth of anaesthesia was monitored by measuring 
the respiratory rate (SA Instruments, Inc., Stony Brook, 
USA). Body temperature was monitored by a rectal 
probe and kept at 37 °C by a heated air stream (37 °C). 
Table  1 shows further details, including group sizes, 
injected dose, and scan durations. PET scans were fol-
lowed by a CT for anatomical orientation.
Two  [11C]mHED scans (one baseline, one for kinetic 
modelling) were excluded from further analysis due 
to technical problems before or during the scan, 
respectively (not included in Table  1). PET data were 
reconstructed using 2-D ordered subsets expecta-
tion maximization in user-defined time frames with a 
voxel size of 0.3875 × 0.3875 × 0.775  mm3 (x, y, axial). 
Images, volumes-of-interest, and the respective time-
activity curves (TAC) as well as NIfTI format files for 
further analysis with R were generated with the dedi-
cated software PMOD (version 3.9, PMOD Technolo-
gies Ltd., Zurich, Switzerland). The nominal voxel size 
of the NIfTI format files was 0.243  mm in all dimen-
sions. Tissue radioactivity was either expressed as kBq/
cm3 or normalized to the injected dose per g body 
weight (kBq/g) and expressed as SUV, assuming a tissue 
density of 1  g/cm3. All activities were decay-corrected 
to the time of tracer injection.
Input function
For kinetic modelling, an arteriovenous shunt sys-
tem was applied to record the coincidences of arte-
rial blood (Twilite, Swisstrace, Zurich, Switzerland) 
Table 1 Details of the PET/CT scans
a Dose in nmol/kg includes the dose of mHED and residual metaraminol








Group size 5 6 3 6 6
Body weight (g) 20.2–23.8 19.6–22.9 27.5–28.9 19.1–24.5 20.5–22.8
Activity (MBq) 2.8–11.5 3.5–13.9 9.2–11.0 3.3–10.8 1.2–8.6
Dose (nmol/kg)a 9.2.0–61.6 9.6–50.0 1.5–2.0 1.6–18.3 3.0–11.8
Scan duration (min) 60 60 60 90 90
Scan start p.i. (min) 1 1 − 1 1 1
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simultaneously with the PET data acquisition (Addi-
tional file  1) [13]. The resulting blood coincidences 
were transformed to Bq/ml with a calibration factor 
determined from simultaneous measurements of an 
 [11C]mHED solution in the PET scanner and the blood 
counter. Next, the blood Bq/ml was multiplied with 
fitted Eq. 2 to calculate the plasma activity concentra-
tion. Finally, the plasma Bq/ml was multiplied with fit-
ted Eq. 1 to receive the parent tracer Bq/ml in plasma, 
which is the input function [14].
Definition of volume‑of‑interest for quantitative analyses
For quantitative analyses, PET data in NIfTI file format 
were read with the R package oro.nifti version 0.9.1, 
and a cube of 36 × 30 × 30 voxels (8.7 × 7.3 × 7.3 mm3) 
including the heart as judged from the PET and CT 
data was cropped. A liver mask was defined including 
all voxels with a slope ≥ − 0.012 SUV/min between 11 
and 48 min p.i. (the slope limit was empirically defined 
by visual inspection of the results, Fig.  1). PET data 
corresponding to the liver mask were excluded. The 
myocardium mask was defined from the remaining 
data as the volume with highest SUV between 3 and 
11  min p.i., corresponding to 0.5% of the individual 
body weight [15]. A typical myocardium data set is 
shown in Fig.  1. Average SUV was calculated for the 
indicated time windows (stated as  SUVstart time–end 
time). The SUV of the neck region was obtained from 
a spherical region of interest with 3 mm radius, placed 
over the shoulders, close to the spine.
Dose dependency of myocardial  [11C]mHED uptake
The dose of combined administered  [11C]mHED 
and metaraminol (precursor for radiosynthesis) at 
half-maximal NET saturation in nmol/kg (D50) was cal-
culated from the myocardial  SUV1–31  min at various 
doses (D).  SUV1–31  min of scans with 20  mg/kg desipra-
mine HCl (66,000  nmol/kg, full NET saturation) and of 
scans for kinetic modelling was included (Table  1; total 
n = 14). Fit parameters were  SUV1–31  min at indefinitely 
low dose  (SUVmax),  SUV1–31 min at full NET saturation, i.e. 
 SUV1–31 min for nondisplaceable tracer  (SUVmin) and D50, 
according to Eq. 3 which was fit to the data with the func-
tion nls of R.
Compartment modelling and statistical analysis
PET kinetic modelling with R was performed with a one- 
and three two-tissue compartment models according to 
Eq. 4,
where CPET is the activity concentration in the PET 
image, either as kBq/cm3 or normalised as SUV, vb is the 
partial volume of blood in the region-of-interest (poten-
tially including interstitial space), Wmodel is the model-
dependent weighting function. Ca is the parent tracer 
activity concentration in the arterial plasma (input func-
tion, kBq/ml, or SUV), and Cb is the whole blood activity 
concentration as calculated from the blood coincidences, 
in kBq/cm3 or as SUV.
The evaluated tissue compartment models are shown 
in Fig.  2. WTCM1 for the one-tissue compartment model 
(TCM1, Fig. 2a) corresponds to K1 × exp(− k2 × t), with t as 
time, K1 and k2 the clearance term from plasma to tissue 
and rate constant back, respectively. WTCM2p and  WTCM2s 
(3)




(4)CPET = (1 − vb) × Wmodel ⊗ Ca + vb × Cb
Fig. 1 Strategy for the definition of the volume-of-interest for myocardial  [11C]mHED uptake. a Transversal planes of a cropped volume including 
the heart, from posterior (top left) to anterior (bottom right).  SUV1–61 min according to colour scale. b Voxel-wise slopes SUV/time between 11 and 
48 min p.i. Slopes according to colour scale. Voxels with slopes ≥ − 0.012 SUV/min were excluded from the volume-of-interest, assuming spill-over 
from liver (liver radioactivity was increasing over time). c From the remaining voxels, the volume with highest SUV between 3 and 11 min p.i., 
corresponding to 0.5% of the individual body weight (i.e. body weight (g) × 0.005  cm3/g). Scan with 9.2 MBq  [11C]mHED (1.5 nmol/kg, including 
metaraminol mass), body weight 27.6 g
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for the two-tissue compartment models with parallel 
(TCM2p, Fig. 2b) and serial (TCM2s, Fig. 2c) tissue com-
partments, respectively, were according to Eqs. 5–10 [16]. 
In the case of the TCM2p, K1, k2, K3, and k4 correspond 
to φ1, θ1, φ2, and θ2, respectively, of Eq. 5. WTCM2v for the 
two-tissue compartment model in Fig.  2d (TCM2v) was 
numerically solved from the differential equation system 
in Eqs. 11 and 12 with the R package deSolve and the ode 
function, with 1-s time intervals.
(5)
WTCM2p/s = ϕ1 × exp(− θ1 × t) + ϕ2 × exp(− θ2 × t)
(6)δ =
√
(k2 + k3 + k4)
2
− 4 × k2 × k4
(7)θ1 = (k2 + k3 + k4 + δ)/2
Besides the transfer clearance or rate constants K1, k2, 
k3 (or K3 for TCM2p), and k4, vb was included as a param-
eter to fit. Equation 3 was fit to the experimental TACs 
applying the optim minimization function of R.
Fits were run with multiple starts with a matrix of 
101 sets of random start parameters between lower and 
upper limits for K1, k2, k3 (or K3), k4, and vb (Additional 
file 1: Table S1). The activity concentrations in the indi-
vidual tissue compartments were simulated by numeri-
cally solving the respective differential equation systems 
for TCM2s and TCM2v and from the analytical solutions 
for TCM2p (the two exponential terms of Eq. 5). Calcu-
lations were performed in parallel on a 32 core worksta-
tion. Best fits were chosen based on the sum of squared 
residues (SSR) between predicted and experimental 
TACs. Best fits were present more than once in the 101 
runs, suggesting that the global minimum was found for 
each scan and model. Correlations between parameters 
were calculated with the lm, cor, and cor.test functions of 
R and were considered significant at p < 0.05.
Results
Chemistry and radiochemistry
The organic synthesis and radiolabelling of the PET 
tracers  [11C]mHED and  [18F]LMI1195 are described in 
Additional file  1.  [11C]mHED was synthesized by direct 
N-methylation of metaraminol with  [11C]methyl triflate 
in 5% water in acetonitrile at room temperature [17]. 
Molar activities were in the range of 48–153 GBq/µmol 
(including residual metaraminol) at the end of synthe-
sis (n = 22). The radiochemical purity was greater than 
99%, as confirmed by HPLC analysis. The identity of the 
tracer was confirmed by co-injection with nonradioactive 
mHED. The total synthesis time from end of bombard-
ment (EOB) was 35–40 min.
The radiosynthesis of  [18F]LMI1195 was carried out 
by a one-pot, two-step reaction sequence consisting of 
nucleophilic fluorination of the corresponding tosylate 
precursor and followed by cleavage of the protect-
ing groups [9]. The molar activities were in the range of 
(8)θ2 = (k2 + k3 + k4 − δ)/2
(9)ϕ1 = K1 × (θ1 − k3 − k4)/δ








= +k3 × C1 − k4 × C2
Fig. 2 Compartment models evaluated in this study. a One-tissue 
compartment model (TCM1). b Model with two parallel tissue 
compartments (TCM2p) both directly accessible from the input 
compartment. c Two-tissue compartment model with the two-tissue 
compartments in series (TCM2s), as applied for neuroreceptor PET. K1 
or k3 would represent NET uptake. In the first case, k3 would represent 
uptake into storage vesicles by vMAT2. In the latter case, K1 would 
represent extravasation into interstitium. d Similar as c but with the 
second-tissue compartment releasing to the input compartment (k4) 
rather than to the first tissue compartment. In this model, K1 would 
represent NET uptake, k3 uptake into storage vesicles by vMAT2, and 
k4 release from storage vesicles into interstitial space (TCM2v, v for 
release from vesicles). Ca,  [
11C]mHED activity concentration in arterial 
plasma (input function)
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45–95  GBq/μmol at the end of synthesis.  [18F]LMI1195 
was obtained in excellent radiochemical purity, and the 
average synthesis time was approximately 80  min from 
the EOB.
[11C]mHED and  [18F]LMI1195 PET and specificity for NET
Mouse myocardium was clearly visualized after  [11C]
mHED or  [18F]LMI1195 administration (Fig.  3a). For 
assessing their uptake mechanism, excess amount of 
desipramine, a NET inhibitor with strong affinity (Ki 
value of 2.76 nM) [18] was used as the blocker. As shown 
in Fig. 3b and Fig. 3a, c blocking effect was observed for 
 [11C]mHED but not for  [18F]LMI1195. These results indi-
cate distinct myocardial uptake mechanisms for  [11C]
mHED and  [18F]LMI1195 in mice, with high selectivity 
for NET in the case of  [11C]mHED but not  [18F]LMI1195. 
Given that 80–90% of norepinephrine (NE) in the synap-
tic cleft is taken up by NET in the human heart [19, 20], 
we subsequently focused on characterizing the kinetics of 
the NET-selective tracer, namely  [11C]mHED.
Dose dependency of  [11C]mHED PET in mice
We performed a dose dependency study to define the 
upper limit of injected mass for linear kinetics, i.e. pro-
portionality between PET signal and activity dose. Since 
metaraminol, the precursor for radiosynthesis, and 
mHED have similar binding affinities for NET (D50 in the 
range of 90–100  nmol/kg in the rat left ventricle wall) 
[21], we did not distinguish between mHED and metara-
minol for calculating the total injected dose in nmol/kg.
As shown in Figs.  3a and  4, myocardial  [11C]mHED 
SUV decreased with increasing dose of injected mass. 
The relationship between  SUV1–31  min and the injected 
total nmol/kg is shown in Fig. 4b. Scans with desipramine 
blocking were included to define the lower plateau of 
the saturation function  (SUVmin in Eq. 3), corresponding 
to unspecific signal at full saturation of NET. Nonlinear 
regression analysis according to Eq.  3 revealed a D50 of 
88.3 nmol/kg (SE 30.3). Fit  SUVmax and  SUVmin were 4.4 
and 1.0, respectively, at a volume-of-interest size of 0.5% 
body volume. Including data from the complete scan 
duration  (SUV1–61  min) revealed D50 = 89.1  nmol/kg (SE 
32.2). We chose ~ 1/10 of D50 as the maximal tolerated 
Fig. 3 Standard PET images of myocardium after i.v. injection of  [11C]mHED or  [18F]LMI1195 in FVB/N mice. a Representative short-axis (left column), 
horizontal long-axis (middle column), and vertical long-axis (right column) PET images at various extents of NET saturation with metaraminol 
(mHED with indication of total mass of  [11C]mHED and metaraminol) or desipramine (20 mg/kg desipramine HCl as indicated) and  [18F]LMI1195 
under baseline conditions or with desipramine. SUV was averaged from 1 to 31 min p.i. b TACs after injection of  [11C]mHED alone (9.2–16.6 nmol/kg, 
including metaraminol mass; n = 3) and  [11C]mHED (9.6–10.5 nmol/kg) + 20 mg/kg desipramine HCl (n = 3). c TACs after injection of  [18F]LMI1195 
alone (mass range, see Table 1; n = 6) and  [18F]LMI1195 (mass range, see Table 1) + 20 mg/kg desipramine HCl (n = 6). Mean values with SD
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dose for further studies, i.e. 10  nmol/kg. At this dose, 
SUV is reduced in theory by 10% as compared to indefi-
nitely low dose. This is within the experimental error 
(Fig.  4). The initial average concentration in the region-
of-interest at 10 nmol/kg would be ~ 50 nM (product of 
SUV and dose in nmol/kg). The  SUV1–31 min of the neck 
region was independent of the dose and similar to myo-
cardium  SUVmin (Additional file 1: Fig. S1).
Radiometabolite and plasma‑to‑whole blood radioactivity 
ratio
After  [11C]mHED i.v. injection, we detected a radiome-
tabolite in plasma and urine which was more polar than 
the parent tracer. Figure  5a shows fparent in plasma over 
time. In the myocardium, only parent  [11C]mHED and 
no radiometabolite were detected (Additional file  1: 
Fig. S2). The ratio ρplasma/blood is shown in Fig. 5b. At time 
t = 0, ρplasma/blood was assumed to be 1/(1-Hkt), with Hkt, 
hematocrit of 0.458 [15], resulting in an initial ρplasma/
blood of 1.85. The ratio decreased to ~ 0.6 at 3  min and 
then increased to a constant value of ~ 1 from ~ 20  min 
onwards. These data indicate substantial blood cell bind-
ing or uptake of  [11C]mHED, while the radiometabolite 
distributed equally between blood cells and plasma. The 
 [11C]mHED accumulation in blood cells may result from 
ATP-driven uptake of  [11C]mHED by the vesicular mon-
oamine transporter 2 (vMAT2) into platelets [22]. Fig-
ure 5c and Fig. 5d show the resulting input functions of 
the three scans for kinetic modelling after correcting the 
blood activity concentration with ρplasma/blood, fparent, and 
normalization to injected dose in kBq/g to reveal SUV.
Myocardial  [11C]mHED follows a two‑tissue compartment 
model
We compared the results of kinetic modelling applying a 
one- and three two-tissue compartment models accord-
ing to Fig.  2. Results were satisfactory by visual inspec-
tion for the two-tissue compartment models (TCM2) 
but not for the one-tissue compartment model (TCM1, 
Fig. 6a). Figure 6b (TCM2p) assumes two parallel mech-
anisms of tracer uptake. This would take into account 
potential desipramine-insensitive uptake as seen for 
 [18F]LMI1195 besides desipramine-sensitive presynap-
tic uptake by NET. Figure 6c shows the two-tissue com-
partment model with the tissue compartments in series 
(TCM2s). In the model described in Fig. 6d (TCM2v), k3 
describes tracer uptake into storage vesicles by vMAT2 
and k4 represents tracer release from synaptic vesicles to 
the interstitial space without kinetic distinction between 
tracer in plasma and interstitial space, i.e. tracer exchange 
between plasma and interstitial space is faster than the 
temporal resolution of the scanner. As expected for the 
three two-tissue compartment models, best fits gener-
ated equal SSR and both K1 and k2 were equal for TCM2s 
and TCM2v. Table 2 shows the averaged fit parameters of 
the 3 scans.
NET‑specific  [11C]mHED uptake is represented by K1
To identify the desipramine-sensitive process and the 
most adequate model, we modelled the TACs of all scans 
shown in Fig. 4, based on one of the three available input 
functions (red curve in Fig. 5d). We assumed that mHED, 
metaraminol, and desipramine had no major influence 
Fig. 4 Dose dependency of  [11C]mHED uptake in the mouse myocardium. a TACs (SUV) of myocardium at the indicated dose of combined  [11C]
mHED and metaraminol. Desipramine, 66′000 nmol/kg, corresponds to 20 mg/kg desipramine HCl. Broken vertical lines indicate 1 and 31 min, 
respectively, the time window for  SUV1–31 min averaging. TACs with shorter time intervals are from the scans for kinetic modelling. b  SUV1–31 min was 
plotted against the dose on logarithmic scale (base 10). Solid line, fit according to Eq. 3 with fit D50 = 88.3 nmol/kg. Broken lines, 95% confidence 
intervals. Broken vertical line indicates 1/10 D50
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on the input function. This assumption is supported by 
the dose- and desipramine-independent  SUV1–31  min of 
the neck region (Additional file 1: Fig. S1). The parameter 
vb was limited between 0.4 and 0.5, according to the fit 
vb of the three scans with input function (Table 2). Two 
representative simulations are shown in Additional file 1: 
Fig. S3. We compared the fit parameters with the injected 
total mass  ([11C]mHED, metaraminol, and desipramine), 
between the models and with the model-independent 
 SUV1–31  min, respectively. The correlations are shown in 
Fig. 7 and Additional file 1: Figs. S4–S6.
For all applied models, K1 was significantly reduced by 
NET saturation with desipramine (66 µmol/kg total mass 
in Fig.  7a), indicating that NET transport is the rate-
determining step for the process described by K1. Tracer 
exchange between plasma and interstitial fluid was thus 
faster than NET transport. The TCM2p model was 
evaluated to identify a potential desipramine-insensitive 
uptake process. In this model, however, both K1 and K3 
were significantly reduced by desipramine, indicating 
that this model is not adequate.
After excluding TCM1 and TCM2p, TCM2s and 
TCM2v remained as candidate models. These two mod-
els revealed the same value for K1 (0.947 ± 0.146 ml/min/
cm3, Table 2) and are thus both valid for the quantifica-
tion of NET function. K1 may even be estimated with a 
one-tissue compartment model. K1 averaged from the 3 
scans with an input function was 0.87 ± 0.11 ml/min/cm3 
for TCM1 (Table  2), < 10% lower than determined with 
TCM2s/TCM2v. Over all 14 analysed scans, K1 of TCM1 
correlated with K1 of TCM2s/TCM2v with a slope of 
0.875 and p < 0.001 (Fig. 7b).
SUV as a parameter to assess NET function
Myocardial SUV was averaged from 1 to 31  min 
 (SUV1–31  min) or 1 to 61  min  (SUV1–61  min). Addi-
tional file  1: Fig.  S7 shows their high correlation with 
r2 = 0.997 and p < 0.001. The comparisons between the 
Fig. 5 Generation of the input function. a Radioactivity fraction of parent tracer in plasma over time. b Ratio of activity concentration between 
plasma and whole blood over time. Lines are fit functions according to Eqs. 1 and 2, respectively, and as shown in the graphs. c Generated 
normalized (SUV) input functions of the 3 scans with blood coincidence measurements. d as c, emphasizing the first 5 min. Black, red, green, input 
functions; grey (lowest peak), whole blood SUV corresponding to the black input function (second lowest peak)
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fit parameters and averaged SUV in Fig.  7c and Addi-
tional file  1: Fig.  S6 show that  SUV1–31  min as well as 
 SUV1–61  min correlated with K1 in all models. In the 
TCM2s and TCM2v, no other parameter correlated sig-
nificantly with  SUV1–31 min or  SUV1–61 min. It should be 
taken into account that 11 of the 14 scans were fit with 
a surrogate input function and that parameters were 
poorly defined for scans with desipramine due to the 
low PET signal. Irrespective of these limitations, the 
data suggest that  [11C]mHED SUV is a valuable param-
eter to assess NET function.
Discussion
While both  [11C]mHED and  [18F]LMI1195 have been 
used for (pre)clinical imaging of cardiac sympathetic 
innervation, species differences have been reported 
for  [18F]LMI1195.  [18F]LMI1195 cardiac uptake was 
desipramine-sensitive in rabbits, nonhuman primates, 
Fig. 6 Representative TAC (black symbols) and fits (red lines) to a one-tissue compartment model (TCM1, a) and three two-tissue compartment 
models, b TCM2p, c TCM2s, d TCM2v. Tracer activity concentrations were simulated for the individual compartments as indicated in the insets (green 
and blue lines). The volume-of-interest corresponded to 0.5% of the individual body volume
Table 2 Fit parameters of four-compartment models for   [11C]mHED myocardial uptake in mice (mean of 3 independent 
scans, SD in parentheses)
TCM1 TCM2p TCM2s TCM2v
K1 (ml/min/cm
3) 0.868 (0.113) 0.499 (0.153) 0.947 (0.146) 0.947 (0.146)
k2 (1/min) 0.029 (0.01) 0.0125 (0.0034) 0.0672 (0.0062) 0.0672 (0.0062)
k3 (1/min), – – 0.0541 (0.0263) 0.0669 (0.0344)
K3 (ml/min/cm
3) – 0.448 (0.114) – –
k4 (1/min) – 0.134 (0.040) 0.0254 (0.0117) 0.0125 (0.0034)
vb (–) 0.497 (0.006) 0.464 (0.035) 0.464 (0.035) 0.464 (0.035)
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and human subjects, but not in rats [9, 23]. In rats, 
myocardial uptake was assigned to the extra-neuronal 
"uptake-2" mechanism. The suspected transporter 
protein(s) mediating "uptake-2" is/are also present in the 
mouse myocardium [7, 24]. We now extend these find-
ings by demonstrating that  [18F]LMI1195 is accumu-
lating in the mouse myocardium, but its uptake is not 
related to NET function, in agreement with the findings 
in rats. In contrast, the efficient blocking of  [11C]mHED 
uptake by desipramine in our study indicates that  [11C]
mHED is highly NET-specific in the mouse myocardium, 
and "uptake-2" of  [11C]mHED is absent or negligible. 
Reported D50 was 91 nmol/kg and 132 nmol/kg in the rat 
and mouse myocardium, respectively, which is consist-
ent with the D50 determined in our study. Our findings 
clearly identify  [11C]mHED as a suitable tracer for in vivo 
imaging of NET function in the mouse heart. Of note, 
however,  [11C]mHED myocardial uptake was dependent 
on the mass dose of combined mHED and the synthesis 
precursor metaraminol, as previously reported [8, 21]. 
Thus, it is advisable to limit the injected mass dose for 
quantitative imaging to 10 nmol/kg, which includes both 
product and residual metaraminol.
After  [11C]mHED injection, we detected one polar 
radiometabolite in the mouse plasma, while more than 
two polar radiometabolites were previously found in 
plasma of rats and guinea pigs [17, 21]. In line with these 
studies, we detected only intact  [11C]mHED in the mouse 
myocardium. The determined plasma to whole blood 
activity ratios after  [11C]mHED injection is comparable 
with the reported values for rats [21].
Both models TCM2s and TCM2v were suitable for 
determining NET transport kinetics (K1). TCM2v may 
represent more adequately the physiological situation of 
vesicle uptake by vMAT2 (k3) and release from the vesi-
cles into the interstitial space (k4) [25]. Vesicular uptake 
of  [11C]mHED was demonstrated in rabbits by Nomura 
et  al. [26], as the vMAT2 inhibitor reserpine reduced 
 [11C]mHED myocardial radioactivity at later time points 
during the scan. Based on our data, we cannot distinguish 
whether  [11C]mHED is released to intra- or extracellu-
lar space or both. As the TCM2s model has an analyti-
cal solution for the weighting function allowing shorter 
computing time, and is a commonly used model for PET, 
it may perfectly serve as a model to quantify mouse myo-
cardial  [11C]mHED uptake by NET. Even a one-tissue 
compartment model may be applied to estimate K1, as 
shown by the good correlation between the respective K1 
and K1 from the TCM2s and TCM2v models.
The fact that K1 was the desipramine-dependent 
parameter in our study indicates that the exchange of 
tracer between plasma and extracellular space was too 
fast to be resolved from the PET data. K1 thus describes 
the kinetics of  [11C]mHED uptake from plasma to 
nerve terminal and not from extracellular space to 
nerve terminal. In this combined process, NET uptake 
is the rate-limiting step as concluded from the strong 
dose dependency. Tracer in the extracellular compart-
ment may be included in our term vb × Cb in Eq. 4. The 
maximal possible clearance parameter from plasma to 
extracellular space equals the plasma flow [27]. Myo-
cardial blood flow under 2% isoflurane anaesthesia 
was 16.9  ml/min/g in a high-resolution spin labelling 
magnetic resonance imaging study [28], corresponding 
to ~ 9  ml/min/cm3 plasma flow, about ninefold higher 
than K1 in our study. As the rate-determining process in 
K1 was NET transport rather than plasma flow, minor 
to moderate changes in myocardial blood flow should 
Fig. 7 a Dose dependency and desipramine sensitivity of K1 in the TCM2s and TCM2v. Dose of combined  [
11C]mHED and metaraminol up to 
61.6 nmol/kg. The highest dose in the plot (66 µmol/kg) corresponds to 20 mg desipramine HCl to fully saturate NET. b K1 of TCM1 correlated with 
K1 of the more complex TCM2s or TCM2v. Slope, intercept, r
2, and p as indicated. c K1 of the TCM2s and TCM2v correlated with  SUV1–31 min.  SUV1–31 min 
may serve as a surrogate parameter for NET transport activity. r2 and p for the data including scans with desipramine ("all data", regression lines) and 
without desipramine scans ("w/o desi"), as indicated. Note that for the estimation of K1, 11 of the 14 scans were analysed with a surrogate input 
function. Red symbols, scan with an input function
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not affect K1 [27]. Nevertheless, K1 may be affected by 
drastically reduced myocardial perfusion, the closer the 
plasma flow approaches K1.
In humans,  [11C]mHED uptake is stronger affected 
by myocardial blood flow than in mice (under isoflu-
rane anaesthesia), as the mean human resting myocar-
dial blood flow is ~ 1  ml/min/g [29] (0.5–0.6  ml/min/g 
plasma flow), while K1 of  [
11C]mHED uptake was up to 
0.6 ml/min/g in a recent PET study [30]. Patients with 
ongoing ischemia may display regionally reduced  [11C]
mHED uptake due to significant perfusion defects [31]. 
In clinical  [11C]mHED PET, information on myocardial 
blood flow is therefore required for quantifying NET 
function and is usually obtained from myocardial per-
fusion imaging prior to  [11C]mHED PET [5].
The recording of the blood radioactivity, e.g. image-
derived from the left ventricle lumen, is recommended 
for a robust readout in clinical  [11C]mHED PET. This 
allows calculating the retention index corresponding 
to the ratio of the regional tissue activity concentra-
tion of  [11C]mHED (kBq/ml tissue) averaged from 30 to 
40 min and the integral of the whole-blood TAC from 
0 to 40 min (kBq·min/ml blood), both derived from the 
PET images [32]. In mice, recording of an arterial input 
function is technically challenging. For studies without 
blood counts recording, we suggest SUV as a surro-
gate of NET uptake activity. Consistent with our data, 
SUV has previously been advocated as a reproducible 
parameter for  [11C]mHED NET uptake in the rat myo-
cardium [33].
There are limitations to this study that should be 
pointed out. First, only three animals were scanned with 
a protocol of kinetic modelling that included an arterio-
venous shunt system which may compromise the conclu-
sions drawn from our study. Second, 11 of the 14 scans 
were fit with a surrogate input function and parameters 
were poorly defined for scans with desipramine due to 
the low PET signal. Third, the animals utilized in this 
study were healthy mice of identical genetic background 
and size. In disease models or genetically modified ani-
mals, the influence of body weight and other confounders 
may affect systemic tracer distribution and, thus, ham-
per the application of SUV. In the latter case, it might be 
more accurate to apply the percentage of injected dose 
per  cm3 (%ID per  cm3) instead of SUV for comparison 
of NET function. Irrespective of these limitations, the 
close relation of K1 with SUV seen in our study suggests 
that myocardial  [11C]mHED uptake in mice is a reliable 
parameter to assess NET function. In contrast, myocar-
dial  [18F]LMI1195 uptake was not related to NET func-
tion in mice. Further studies are required to better define 
the mechanism by which  [18F]LMI1195 accumulates in 
the mouse myocardium.
Conclusion
Our data indicate that  [11C]mHED kinetics follow a 
two-tissue compartment model in the mouse myocar-
dium, with K1 describing NET transport kinetics. Our 
results further unveil a close relation of K1 with SUV 
in normal mice, suggesting that SUV might be a reli-
able parameter for NET function, thereby eliminating 
the need for arterial blood sampling. Given that NET 
function is essential for cardiac sympathetic integrity, 
our findings encourage a broader application of  [11C]
mHED PET imaging in murine models in cardiovascu-
lar research.
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